LumiraDx Presents LumiraDx Point of Care Instrument at IFCC EUROMEDLAB

LumiraDx (London, UK) participated in the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB) hosted by the German Society of Clinical Chemistry and Laboratory Medicine (DGKL), one of the oldest national societies devoted to clinical chemistry and laboratory medicine. EUROMEDLAB 2022 combined a large scientific program with educational workshops and symposia providing cutting edge science and breakthrough technologies. Alongside this, there was an industry exhibition showcasing the latest innovations in the field of clinical chemistry, diagnostics, clinical microbiology and laboratory informatics.

LumiraDx exhibited at EUROMEDLAB live for the first time to present its LumiraDx point of care instrument which offers a broad menu of lab-comparable results on a single, portable diagnostic platform. The LumiraDx Platform is an innovative, next generation point of care diagnostic system that combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care. The platform is designed to go wherever the patient is, whether this is in a hospital, medical office, pharmacy, or in other non-traditional settings such as schools or airports.

The LumiraDx Platform menu includes point of care tests for COVID-19 Antibody, INR and D-Dimer - with high levels of accuracy comparable to central lab-based tests - all of which have achieved CE Mark and are commercially available in Europe. LumiraDx has also developed a high sensitivity antigen test for COVID-19 on the LumiraDx Platform. The LumiraDx COVID-19 antigen test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and achieved CE Mark. The LumiraDx Platform and COVID-19 antigen tests are also available in Japan and Brazil and has been rolled out in more than 60 countries globally.

Related Links:
LumiraDx 

Visit expo >

Gold Member

Serological Pipet Controller

PIPETBOY GENIUS

Gold Member

Troponin T QC

Troponin T Quality Control

New

HIV-1 Test

HIV-1 Real Time RT-PCR Kit

New

Total 25-Hydroxyvitamin D₂ & D₃ Assay

Total 25-Hydroxyvitamin D₂ & D₃ Assay